Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
Launched by UNIVERSITY OF JAZAN · Mar 28, 2025
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult (≥ 18 year) patients who were admitted to ICU with sepsis syndromes (sepsis or septic shock), according to sepsis-3 definition.
- Exclusion Criteria:
- • Missing data
- • Renal transplant or tumor
- • Solitary kidney
- • Established CKD
- • Obstructive uropathy
- • Renal artery stenosis
- • Pregnancy
About University Of Jazan
The University of Jazan is a leading academic institution in Saudi Arabia dedicated to advancing healthcare research and education. With a strong emphasis on clinical trials, the university aims to enhance medical knowledge and improve patient outcomes through innovative studies. The institution fosters collaboration between multidisciplinary teams of researchers, healthcare professionals, and students, ensuring a rigorous and ethical approach to clinical research. By leveraging its state-of-the-art facilities and expertise, the University of Jazan is committed to contributing valuable insights to the global medical community and addressing pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Al 'Usaylah, , Saudi Arabia
Patients applied
Trial Officials
Mohammed Alshrahili, MSc
Principal Investigator
Armed Forces Hospitals, Southern Region, Saudi Arabia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported